“This is just part of our commitment to develop treatments for everybody with cystic fibrosis. Tessera Therapeutics, founded and created by life sciences VC staple Flagship Pioneering, is building a war chest with a fresh 300 million for its trio of gene writing platforms. “There have been transformative medicines that have benefited people with cystic fibrosis,” but not everyone, said Michael Boyle, president and chief executive of the foundation. To report an adverse event or side effect call 1-84. Prescribing Information, including Boxed Warning where applicable. To learn more, please follow the links below to visit the individual product websites or view the Full U.S. Nonetheless, 7 to 10 percent of patients don’t benefit from the treatments because they have rare mutations that cause the condition. Our products make a difference for patients and provide solutions for prescribers. They include Trikafta, a three-medicine combination approved in 2019 by the Food and Drug Administration, with a list price of $311,000 a year. Since 2011, Boston-based Vertex Pharmaceuticals has won approval of four cutting-edge drugs that have made the disease manageable for about 90 percent of patients. More than 70,000 people live with cystic fibrosis worldwide, including over 30,000 in the US, according to the foundation. Fundamentals See More Market Capitalization, K 2,169,097 Shares Outstanding, K 48,580 Annual Sales, 273,300 K Annual Income, 117,020 K 60-Month Beta 0. People with the disease have inherited two copies of the defective cystic fibrosis gene, one copy from each parent. Severino currently serves as Chief Executive Officer of Tessera Therapeutics, the biotechnology company pioneering GENE WRITING technology which consists of. TSRA - Tessera Technologies Stock Price - Tessera Technologies (TSRA) Try Excel Help Go To: Full Chart Realtime quote and/or trades are not sourced from all markets.
Cystic fibrosis is an inherited disease in which thick, sticky mucus accumulates in organs, including the digestive system and, most dangerously, lungs. SANA stock pipeline and financial data - Sana Biotechnology Inc.
0 kommentar(er)
